Last reviewed · How we verify
Sorilux 0.005 % Topical Foam
Sorilux 0.005% Topical Foam, marketed by Skin Sciences, PLLC, holds a position in the dermatological market with its unique formulation. The drug's key strength lies in its key composition patent, which is set to expire in 2028, providing a period of market exclusivity. The primary risk is the potential increase in competition post-patent expiry, which could impact market share and revenue.
At a glance
| Generic name | Sorilux 0.005 % Topical Foam |
|---|---|
| Also known as | Calcipotriol Foam |
| Sponsor | Skin Sciences, PLLC |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color (PHASE4)
- Combination Topical Therapy for Treatment of Scalp Actinic Keratoses (EARLY_PHASE1)
- Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis (PHASE4)
- To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis). (PHASE3)
- Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis (PHASE4)
- Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis (PHASE1)
- Enstilar in Combination With Biologic Agents (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sorilux 0.005 % Topical Foam CI brief — competitive landscape report
- Sorilux 0.005 % Topical Foam updates RSS · CI watch RSS
- Skin Sciences, PLLC portfolio CI